Bristol-Myers Squibb Canada

21 articles about Bristol-Myers Squibb Canada

• Health Canada Has Approved (Pr)SOTYKTU (deucravacitinib tablets), an Oral Treatment for Adults with Moderate to Severe Plaque Psoriasis

  11/28/2022

  Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved SOTYKTU (deucravacitinib tablets), the first-in-its-class oral tablet for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

• Health Canada Has Approved ZEPOSIA (ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis

  4/12/2022

  Bristol Myers Squibb Canada (BMS) today announced that Health Canada has approved ZEPOSIA® (ozanimod) capsules for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent.

• 

  Fred Frank, 'Founding Father' of Biotech, Dead at 89

  9/13/2021

  Frederick Frank, an innovator of biotech investment who played a key role in Roche’s acquisition of Genentech and the merger that formed Bristol-Myers Squibb, has died.

• Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living With Myelodysplastic Syndromes

  2/16/2021

  REBLOZYL®, an erythroid maturation agent, is the first and only of its kind approved for use in Canada

• Health Canada Approves REBLOZYL® (luspatercept), New Class of Treatment for Adult Patients Living with Beta Thalassemia

  9/29/2020

  Bristol Myers Squibb Canada and Acceleron Pharma Inc. announced that Health Canada has approved REBLOZYL® for the treatment of adult patients with red blood cell transfusion-dependent anemia associated with beta-thalassemia.1 REBLOZYL® is the first and only erythroid maturation agent in Canada, representing a new class of treatment for eligible patients.

• Health Canada Approves REBLOZYL, New Class of Treatment for Adult Patients Living with Beta Thalassemia

  9/29/2020

  REBLOZYL ® is the first and only erythroid maturation  agent approved for use in Canada

• Health Canada Approves INREBIC® (fedratinib), First New Treatment in Nearly a Decade for Patients Living with Myelofibrosis

  9/21/2020

  INREBIC® provides new, once-daily oral option for patients affected by rare bone marrow cancer

• Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma

  7/9/2018

  OPDIVO® (nivolumab) + YERVOY® (ipilimumab) combination is the first and only treatment to show significantly superior overall survival versus current standard of care in intermediate- and poor-risk advanced or metastatic renal cell carcinoma

• Bristol-Myers Squibb Canada Release: Manitoba To Cover Immuno-Oncology Treatment OPDIVO (Nivolumab) For Three Tumour Types

  3/15/2017

• Bristol-Myers Squibb Canada Release: National Agreement Reached Between Pan-Canadian Pharmaceutical Alliance And Bristol-Myers Squibb For Immuno-Oncology Treatment OPDIVO (Nivolumab)

  2/10/2017

• Bristol-Myers Squibb Canada Release: First-Ever Combination Of Two Immuno-Oncology Agents For Metastatic Melanoma Approved By Health Canada

  11/1/2016

• Bristol-Myers Squibb Canada Release: Canada's Health Technology Assessment Agency Gives Positive Recommendation For OPDIVO To Treat Non-Small Cell Lung Cancer

  6/9/2016

• Bristol-Myers Squibb Canada Release: Health Canada Approves DAKLINZA (Daclatasvir) For Difficult-To-Treat Hepatitis C Patient Populations

  5/24/2016

• Bristol-Myers Squibb Canada Release: Health Canada Approves OPDIVO (nivolumab) For The Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer

  3/1/2016

• Roche Should Head Back to the Acquisition Trail, Abbvie or Bristol-Myers Squibb Canada Should be Targeted: Analyst

  9/28/2012

• FDA Approves Bristol-Myers Squibb Canada's Self-injectable Form of RA Therapy Orencia

  8/1/2011

• Bristol-Myers Squibb Canada Relocates to Technoparc Montreal

  3/19/2009

• ImClone Systems Incorporated Announces ERBITUX(R) Commercial Launch in Canada for Advanced Colorectal Cancer

  10/29/2008

• Bristol-Myers Squibb Canada Commercializes ERBITUX(TM) for Advanced Colorectal Cancer

  10/29/2008

• Bristol-Myers Squibb Canada Profit Triples on Sale of Device Unit

  10/23/2008